02384nas a2200241 4500000000100000008004100001260001200042653003700054653002400091653001400115653002700129653002300156653003400179100002400213700001100237700001500248245015200263856008000415300000900495490000700504520161700511022001402128 2023 d c05/202310aMycobacterium leprae (M. leprae)10aSchwann cells (SCs)10aInfection10aIntracellular pathogen10aleprosy recurrence10aphenolic glycolipid-I (PGL-I)1 aChavarro-Portillo B1 aSoto C1 aGuerrero M00aMycobacterium leprae's Infective Capacity Is Associated with Activation of Genes Involved in PGL-I Biosynthesis in a Schwann Cells Infection Model. uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218259/pdf/ijms-24-08727.pdf a1-180 v243 a
Peripheral nerves and Schwann cells (SCs) are privileged and protected sites for initial colonization, survival, and spread of leprosy bacillus. Mycobacterium leprae strains that survive multidrug therapy show a metabolic inactivation that subsequently induces the recurrence of typical clinical manifestations of leprosy. Furthermore, the role of the cell wall phenolic glycolipid I (PGL-I) in the M. leprae internalization in SCs and the pathogenicity of M. leprae have been extensively known. This study assessed the infectivity in SCs of recurrent and non-recurrent M. leprae and their possible correlation with the genes involved in the PGL-I biosynthesis. The initial infectivity of non-recurrent strains in SCs was greater (27%) than a recurrent strain (6.5%). In addition, as the trials progressed, the infectivity of the recurrent and non-recurrent strains increased 2.5- and 2.0-fold, respectively; however, the maximum infectivity was displayed by non-recurrent strains at 12 days post-infection. On the other hand, qRT-PCR experiments showed that the transcription of key genes involved in PGL-I biosynthesis in non-recurrent strains was higher and faster (Day 3) than observed in the recurrent strain (Day 7). Thus, the results indicate that the capacity of PGL-I production is diminished in the recurrent strain, possibly affecting the infective capacity of these strains previously subjected to multidrug therapy. The present work opens the need to address more extensive and in-depth studies of the analysis of markers in the clinical isolates that indicate a possible future recurrence.
a1422-0067